

K 101438

**Special 510(k) Summary of Safety and Effectiveness**

JUN 17 2010

Proprietary Name: T2 Greater Trochanter Nail (GTN)  
Common Name: Intramedullary Nail, Femoral Nail  
Classification Name and Reference: Intramedullary Fixation Rod  
21 CFR §888.3020  
Proposed Regulatory Class: Class II  
Device Product Code: HSB: Rod, Fixation, Intramedullary and Accessories  
For Information contact: Melissa Matarese, Regulatory Affairs Associate  
Howmedica Osteonics Corp.  
325 Corporate Drive  
Mahwah, NJ 07430  
Phone: (201) 831-5116 Fax: (201) 831-4116

Date Prepared: June 17, 2010

**Predicate Device Identification**

The T2 (Greater Trochanter Nail) is a cylindrical, cannulated titanium alloy tube, slightly bowed to accommodate the shape of the femur. The T2 GTN may be inserted into the femoral canal using either a retrograde or antegrade surgical approach.

**Description of Device Modification**

The predicate device is the T2 Femoral Nail A/R which was cleared for sale under K010801 in April 2001. The intended use and indications are the same. The difference between T2 GTN and the predicate is that the nail entry point is in the greater trochanter for T2 GTN, whereas for the T2 Femoral Nail A/R it is in the piriformis fossa.

**Intended Use**

The subject T2 GTN, like the predicate Osteo IC R/A Femoral Nail System known as the T2 Nail System, is a fracture fixation device comprised of femoral nails and the related locking screws, compression screws, and end caps. The subject and predicate devices are intended to assist with internal fracture fixation with minimal soft tissue irritation. This device is utilized as an aid to healing, not as a substitute for normal intact bone and tissue.

**Indications for Use**

The subject and predicate devices are indicated for long bone fracture fixation, specifically femoral fracture fixation, which may include the following:

8 p. 1 of 2

- Open and closed femoral fractures
- Pseudoarthrosis and correction osteotomy
- Pathologic fractures, impending pathologic fractures, and tumor resections
- Ipsilateral femur fractures
- Fractures proximal to a total knee arthroplasty
- Nonunions and malunions

**Statement of Substantial Equivalence:**

Testing demonstrated comparable mechanical properties of the subject T2 GTN Femoral Nail System to the predicate T2 Nail in K010801. The following tests were conducted: Functionality test and influence of cannulated compression screws on the Fatigue Strength, 4-Point Bending Test, Dynamic Testing of Nail Strength, End Cap Testing, and Dynamic Fatigue Strength of T2 GTN Nails, End Product Test of fully threaded screw and shaft screw, Screw Insertion Test.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room W-066-0609  
Silver Spring, MD 20993-0002

Howmedica Osteonics Corp.  
c/o Ms. Melissa A. Matarese  
Regulatory Affairs Associate  
325 Corporate Drive  
Mahwah, New Jersey 07430

Re: K101438

**JUN 17 2010**

Trade/Device Name: T2 Greater Trochanteric Nail (GTN)  
Regulation Number: 21 CFR 888.3020  
Regulation Name: Intramedullary Fixation Rod  
Regulatory Class: Class II  
Product Code: HSB  
Dated: May 19, 2010  
Received: May 24, 2010

Dear Ms. Matarese:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mark N. Melkerson". The signature is fluid and cursive, with a large initial "M" and "N".

Mark N. Melkerson

Director

Division of Surgical, Orthopedic

and Restorative Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K 101438

Device Name: T2 GTN

### Indications For Use:

The subject and predicate devices are indicated for long bone fracture fixation, specifically femoral fracture fixation, which may include the following:

- Open and closed femoral fractures
- Pseudoarthrosis and correction osteotomy
- Pathologic fractures, impending pathologic fractures, and tumor resections
- Ipsilateral femur fractures
- Fractures proximal to a total knee arthroplasty
- Nonunions and malunions

Prescription Use X

(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_

(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF  
NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of 1

*[Signature]* for *mxm*  
(Division Sign-Off)  
Division of Surgical, Orthopedic,  
and Restorative Devices

510(k) Number K101438